Literature DB >> 2792744

Affective, substance use, and anxiety disorders in persons with arthritis, diabetes, heart disease, high blood pressure, or chronic lung conditions.

K B Wells1, J M Golding, M A Burnam.   

Abstract

The authors estimated the sex- and age-adjusted prevalence of affective, substance use, and anxiety disorders in persons in a general population sample who identified themselves as having arthritis, diabetes, heart disease, high blood pressure, chronic lung disease, or no chronic medical conditions. Persons who reported ever having arthritis, heart disease, chronic lung disease, or high blood pressure had a significantly increased adjusted prevalence of each of the three groups of lifetime psychiatric disorders, relative to a no-chronic conditions comparison group (each p less than 0.05). Persons who ever had diabetes had an increased adjusted prevalence of lifetime affective and anxiety but not substance use disorder. Persons with current (i.e., active) arthritis, heart disease, or high blood pressure had a significantly increased adjusted prevalence of recent (6-month) anxiety disorder, whereas those with current chronic lung disease had an increased adjusted prevalence of recent affective and substance use but not anxiety disorder.

Entities:  

Mesh:

Year:  1989        PMID: 2792744     DOI: 10.1016/0163-8343(89)90119-9

Source DB:  PubMed          Journal:  Gen Hosp Psychiatry        ISSN: 0163-8343            Impact factor:   3.238


  23 in total

1.  Impact of pain severity and location on health-related quality of life.

Authors:  Dennis C Ang; Kurt Kroenke; Colleen A McHorney
Journal:  Rheumatol Int       Date:  2005-08-11       Impact factor: 2.631

2.  Use of psychiatric services by patients in a general hospital.

Authors:  R Mayou; V Seagroatt; M Goldacre
Journal:  BMJ       Date:  1991-10-26

3.  Predictors of clinical pain in fibromyalgia: examining the role of sleep.

Authors:  Ryan J Anderson; Christina S McCrae; Roland Staud; Richard B Berry; Michael E Robinson
Journal:  J Pain       Date:  2012-03-03       Impact factor: 5.820

Review 4.  Screening and brief intervention for unhealthy substance use in patients with chronic medical conditions: a systematic review.

Authors:  Christine Timko; Calvin Kong; Lisa Vittorio; Michael A Cucciare
Journal:  J Clin Nurs       Date:  2016-05-03       Impact factor: 3.036

5.  Non-insulin-dependent diabetes mellitus and depression in a middle-aged Finnish population.

Authors:  U Rajala; S Keinänen-Kiukaanniemi; S L Kivelä
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  1997-08       Impact factor: 4.328

6.  Anxiety and depression symptoms in arterial hypertension: the influence of antihypertensive treatment. the HUNT study, Norway.

Authors:  Aslak Johansen; Jostein Holmen; Robert Stewart; Ottar Bjerkeset
Journal:  Eur J Epidemiol       Date:  2011-12-20       Impact factor: 8.082

7.  Anxiety symptomatology and perceived health in African American adults: moderating role of emotion regulation.

Authors:  Sierra E Carter; Rheeda L Walker
Journal:  Cultur Divers Ethnic Minor Psychol       Date:  2014-07

8.  Depression as a risk factor for cardiac events in established coronary heart disease: a review of possible mechanisms.

Authors:  R M Carney; K E Freedland; M W Rich; A S Jaffe
Journal:  Ann Behav Med       Date:  1995

9.  Mental-physical co-morbidity and its relationship with disability: results from the World Mental Health Surveys.

Authors:  K M Scott; M Von Korff; J Alonso; M C Angermeyer; E Bromet; J Fayyad; G de Girolamo; K Demyttenaere; I Gasquet; O Gureje; J M Haro; Y He; R C Kessler; D Levinson; M E Medina Mora; M Oakley Browne; J Ormel; J Posada-Villa; M Watanabe; D Williams
Journal:  Psychol Med       Date:  2008-03-26       Impact factor: 7.723

10.  Age patterns in the prevalence of DSM-IV depressive/anxiety disorders with and without physical co-morbidity.

Authors:  K M Scott; M Von Korff; J Alonso; M Angermeyer; E J Bromet; R Bruffaerts; G de Girolamo; R de Graaf; A Fernandez; O Gureje; Y He; R C Kessler; V Kovess; D Levinson; M E Medina-Mora; Z Mneimneh; M A Oakley Browne; J Posada-Villa; H Tachimori; D Williams
Journal:  Psychol Med       Date:  2008-05-19       Impact factor: 7.723

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.